Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Lenvatinib With or Without Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer
NCT05935579Phase 2Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Dec 2022
- Primary completion
- Dec 2023
- Modality
- Antibody Conjugates, Small Molecules, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, lenvatinib in biliary tract cancer (BTC), sponsored by Peking Union Medical College Hospital. Status: unknown.
02
Drugs
durvalumablenvatinib
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT05935579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05935579.